A Form 4 filed with the SEC on September 3, 2026, reports that Lars Holtug, a director of Ascendis Pharma A/S (NASDAQ:ASND), sold 236 ordinary shares on September 2, 2026.
Key Highlights
- Reporting person: Lars Holtug, listed as a director of Ascendis Pharma A/S.
- Transaction: 236 ordinary shares disposed of (transaction code S) on September 2, 2026.
- Sale price: $264.1296 per share, as reported in the filing.
- Post-transaction ownership: 4,000 ordinary shares held directly following the reported transaction.
- Filing date: September 3, 2026, signed by Michael Wolff Jensen as attorney-in-fact for Lars Holtug.
Director Share Sale Details for Ascendis Pharma A/S
According to the Form 4 filing, Lars Holtug, identified as a director of Ascendis Pharma A/S, disposed of 236 ordinary shares on September 2, 2026, at a price of $264.1296 per share. The transaction is coded "S," indicating an open-market sale. The filing was submitted to the SEC on September 3, 2026.
Following the reported transaction, the filing discloses that Holtug directly holds 4,000 ordinary shares of Ascendis Pharma A/S. No indirect holdings or derivative securities are reported in the filing. No Table II derivative security transactions were listed.
The form was signed by Michael Wolff Jensen as attorney-in-fact for Lars Holtug. Ascendis Pharma A/S trades on NASDAQ under the symbol ASND. The filing does not indicate whether the transaction was made pursuant to a Rule 10b5-1 trading plan, as the relevant checkbox on the form was not checked.
What Was Disclosed
The filing reports a single open-market sale of 236 ordinary shares by Ascendis Pharma director Lars Holtug at $264.1296 per share on September 2, 2026, leaving him with a direct beneficial ownership of 4,000 shares.




Please wait processing your request...